Same Day Diagnosis of Extrapulmonary TB (TB Serositis and TB Meningitis).

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

2160 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-03-16

Study Completion Date

2026-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Extrapulmonary TB (EPTB) accounts for nearly 30% of TB cases in HIV endemic settings, such as South Africa. The diagnosis of extrapulmonary TB is complicated by the poor performance of Gene Xpert and TB Culture in extrapulmonary fluid (30-50% sensitive), as well as the poor specificity of ADA. We can therefore not reliably use these tests to diagnose EPTB as effectively as we use them in sputum samples. The current best practice for diagnosing pleural TB is to perform a pleural biopsy, which is both invasive and costly. A rapid, easy to use test is needed to allow accurate and fast diagnosis of EPTB. Interferon-gamma is released at high concentrations in extrapulmonary fluid in active EPTB. Antrum Biotech has developed the IRISA-TB assay (validated and SAHPRA licenced) for the diagnosis of EPTB.

The study will assess the real-world performance of IRISA-TB compared to ADA, Gene Xpert, and TB Culture when used to diagnose EPTB. We will evaluate IRISA-TB's performance in the following patient groups:

* Suspected TB pleural effusion (n= 650)
* Suspected TB pericardial effusion (n= 280)
* Suspected TB peritonitis (n= 200)
* Suspected TB meningitis (n = 1040) As part of our evaluation, we will ask clinicians who treat these patients to provide their feedback on IRISA-TB. We will ask them to indicate to what extent the IRISA-TB test helped them to make treatment decisions. Finally, we will conduct an economic assessment to determine the true cost of diagnosing and treating EPTB to the health system and patients, and we will determine how IRISA-TB could potentially result in cost savings.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Host Blood RNA Signatures for Diagnosis of TB

NCT05542511

Tuberculosis Lower Respiratory Infection

ACTIVE_NOT_RECRUITING

Tuberculosis Prevention for HIV Infected Adults

NCT00057122

HIV Infections Tuberculosis

COMPLETED PHASE3

Assessing the Ability of the T-SPOT®.TB Test

NCT03929705

Tuberculosis (TB)

COMPLETED

Gene Expression Profiles in Spinal Tuberculosis.

NCT05610098

Tuberculosis, Spinal Tuberculosis, Osteoarticular Tuberculosis +11 more

RECRUITING

High vs. Standard Dose Rifampicin for Effusive Tuberculous Pericarditis

NCT04521803

Tuberculous Pericarditis HIV Status

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tuberculosis, Extrapulmonary

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Prospective cohort

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with suspected extrapulmonary tuberculosis

Patients with pleural, pericardial, or peritoneal effusions due to suspected extrapulmonary tuberculosis and those with suspected TB meningitis.

Group Type EXPERIMENTAL

IRISA-TB

Intervention Type DIAGNOSTIC_TEST

ELISA-based assay that detects interferon-gamma concentrations in extrapulmonary fluid in active TB.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

IRISA-TB

ELISA-based assay that detects interferon-gamma concentrations in extrapulmonary fluid in active TB.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female participants 18 years and over attending health care facility with symptoms of TB.
2. Serosal or CSF fluid sample provided to NHLS with sufficient volume to perform SOC tests + 1ml.
3. Patients in whom extrapulmonary TB is part of the treating clinicians' differential diagnosis.

Exclusion Criteria

1. Volunteers who refuse to sign informed consent and/or provide clinical details (Proxy consent will be obtained for participants who are incapacitated, with a follow up consent when they have recovered their capacity to consent)
2. Patients with current significant history of substance or alcohol abuse that may impact study visits.
3. Patients who are unable to communicate by telephone or who do not have a current active traceable contact number.
4. Patients not willing to undergo an HIV test.
5. Patients whose fluid sample volumes are insufficient to perform standard of care testing in addition to IRISA-TB
6. Positive sputum GXP within 2 weeks prior to serosal fluid or CSF sampling.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No